Skip to main content

Animations

MJFF Publications

4441 - 4450 of 6422 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2022
  • 2025
  • 2025
  • 2023
  • 2024
  • 2024
  • 2024
  • 2024
  • Summary Details
    OPEN
    Title: Analysis of factors associated with early stage Parkinson’s disease based on daily activities and sleeping behaviour disorder
    Journal Name: Journal of Physics: Conference Series
    Publisher: IOP Publishing
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1088/1742-6596/1722/1/012045
    Citation Count: 1
  • Summary Details
    OPEN
    Title: NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson’s disease
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/brain/awab214
    Citation Count: 15
  • Summary Details
    OPEN
    Title: Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/brain/awac187
    Citation Count: 38
  • Summary Details
    OPEN
    Title: α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000210279
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Segregated basal ganglia output pathways correspond to genetically divergent neuronal subclasses
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.celrep.2025.115454
    Citation Count: 1
  • Summary Details
    OPEN
    Title: DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease
    Journal Name: Progress in Neurobiology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.pneurobio.2023.102414
    Citation Count: 12
  • Summary Details
    OPEN
    Title: The R1441C-Lrrk2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner in mice
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.adl1535
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease
    Journal Name: Clinical and Translational Science
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1111/cts.70066
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa‐Induced Dyskinesia
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.29960
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: A comparative study with tranylcypromine
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2024.107158
    Citation Count: 2
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.